Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate. Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. Cisatracurium is an R-cis-R-cis isomer of atracurium and has approximately 3 times its neuromuscular blocking potency. Compared to atracurium, cisatracurium produces a lower degree of histamine release.
Cisatracurium is indicated as an adjunct to general anesthesia to facilitate tracheal intubation in adults and pediatric patients 1 month to 12 years of age. Cisatracurium is also indicated to provide skeletal muscle relaxation during surgery in adults and pediatric patients 2 to 12 years of age as a bolus or infusion maintenance and for mechanical ventilation in the ICU in adults.
Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Xiangya Hospital of Central South University, Changsha, Hunan, China
Azienda Ospedaliera di Padova, Padova, Italy
Assistance Publique Hopitaux de Marseille, Marseille, France
Al-zahra university hospital, Isfahan, Iran, Islamic Republic of
Rady Children's Hospital, San Diego, California, United States
Réanimation chirurgicale, Nimes, France
Réanimation Polyvalente, Avignon, France
Hôpital de la Tronche - Réanimation médicale, Grenoble, France
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.